4//SEC Filing
Smith Christopher M 4
Accession 0001077183-25-000039
CIK 0001077183other
Filed
Feb 24, 7:00 PM ET
Accepted
Feb 25, 4:37 PM ET
Size
18.3 KB
Accession
0001077183-25-000039
Insider Transaction Report
Form 4
Smith Christopher M
Chief Executive Officer
Transactions
- Exercise/Conversion
Restricted Stock Unit
2025-02-23−57,413→ 114,826 totalExercise: $0.00→ Common Stock (57,413 underlying) - Exercise/Conversion
Common Stock
2025-02-23+57,413→ 655,652 total - Tax Payment
Common Stock
2025-02-23−14,067→ 641,585 total
Holdings
- 96,127
Restricted Stock Unit
Exercise: $0.00→ Common Stock (96,127 underlying) - 269,841
Stock Option (Right to Buy)
Exercise: $19.65Exp: 2030-05-11→ Common Stock (269,841 underlying) - 287,940
Stock Option (Right to Buy)
Exercise: $16.45Exp: 2034-02-23→ Common Stock (287,940 underlying) - 694,444
Stock Option (Right to Buy)
Exercise: $12.62Exp: 2029-08-15→ Common Stock (694,444 underlying) - 144,190
Performance Stock Unit
Exercise: $0.00From: 2026-05-11→ Common Stock (144,190 underlying) - 172,240
Performance Stock Unit
Exercise: $0.00From: 2027-02-23→ Common Stock (172,240 underlying)
Footnotes (10)
- [F1]Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting.
- [F10]On February 23, 2024, Mr. Smith was granted 172,240 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 258,360. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
- [F2]Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units.
- [F3]On February 23, 2024, Mr. Smith was granted 172,239 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
- [F4]Once vested, the shares of common stock are not subject to expiration.
- [F5]On August 15, 2022, Mr. Smith was granted 694,444 stock options. These options vest ratably over the first four anniversary dates of the grant date.
- [F6]On May 11, 2023, Mr. Smith was granted 269,841 stock options. These options vest ratably over the first three anniversary dates of the grant date.
- [F7]On May 11, 2023, Mr. Smith was granted 144,190 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
- [F8]On May 11, 2023, Mr. Smith was granted 144,190 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 216,285. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company.
- [F9]On February 23, 2024, Mr. Smith was granted 287,940 stock options. These options vest ratably over the first three anniversary dates of the grant date.
Documents
Issuer
NEOGENOMICS INC
CIK 0001077183
Entity typeother
Related Parties
1- filerCIK 0001436707
Filing Metadata
- Form type
- 4
- Filed
- Feb 24, 7:00 PM ET
- Accepted
- Feb 25, 4:37 PM ET
- Size
- 18.3 KB